STOCK TITAN

Kura Oncology (KURA) SEC Filings, Oct-Nov 2025

KURA NASDAQ

Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.

Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.

Rhea-AI Summary

Kura Oncology, Inc. (KURA) reported insider equity activity by its Chief Legal Officer on a Form 4. On 11/13/2025, 48,900 shares of common stock were acquired at a price of $0, reflecting vesting tied to performance-based restricted stock units (PSUs). On 11/14/2025, 8,804 shares were sold at $11.1769 in a sell-to-cover transaction for taxes related to this vesting. These PSUs were granted on May 31, 2023 and vest based on specified development milestones and continued service. Following the reported transactions, the officer beneficially owned 188,139 shares of Kura Oncology common stock directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
insider
-
Rhea-AI Summary

Kura Oncology, Inc. (KURA) President and CEO Troy E. Wilson reported the vesting of 182,500 shares of common stock on 11/13/2025. These shares relate to performance-based restricted stock units (PSUs) originally granted on May 31, 2023, which vest upon achievement of specified development milestones and the one-year anniversary of each milestone, subject to continued service. The filing states that the performance criteria for one development milestone were met on November 13, 2025, triggering vesting of one-sixth of the underlying shares at a price of $0 per share. Following this transaction, Wilson beneficially owns 429,353 shares directly, 279,194 shares indirectly through the One Fish Two Fish Revocable Trust, and 300,000 shares indirectly through the Lorax Charitable Remainder Unitrust.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
insider
-
Rhea-AI Summary

Kura Oncology, Inc. reported an insider equity transaction by its Chief Medical Officer, Mollie Leoni. On 11/13/2025 she acquired 82,500 shares of common stock at a reported price of $0 following the vesting of performance-based restricted stock units tied to a development milestone. On 11/14/2025 she sold 15,485 shares of common stock at $11.1769 per share in a sell-to-cover transaction for taxes related to that vesting. After these transactions, she directly beneficially owned 225,454 shares of Kura Oncology common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
insider
Rhea-AI Summary

Kura Oncology, Inc. (KURA) senior vice president of finance and accounting Thomas Doyle reported equity transactions in a Form 4. On 11/13/2025, he acquired 24,967 shares of common stock at $0, raising his direct holdings to 134,796 shares. On 11/14/2025, he sold 4,539 shares of common stock at $11.1769 per share, leaving 130,257 shares held directly. The sale was described as a sell-to-cover for taxes tied to the vesting of performance-based restricted stock units granted on May 31, 2023, after a specified development milestone was met on November 13, 2025. He also holds 500 shares indirectly through his spouse's 401(k).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
insider
-
Rhea-AI Summary

Kura Oncology, Inc. (KURA) reported an insider equity transaction by its Chief Operating Officer. On 11/13/2025, the officer acquired 48,900 shares of common stock at $0, reflecting the vesting of performance-based restricted stock units after a development milestone was achieved. On 11/14/2025, 6,902 shares were sold at $11.1769 in a sell-to-cover transaction for taxes tied to this vesting. Following these transactions, the officer directly beneficially owned 105,373 shares of Kura Oncology common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.17%
Tags
insider
-
Rhea-AI Summary

Kura Oncology (KURA) announced that the FDA granted full approval of KOMZIFTI (ziftomenib) for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. KOMZIFTI is the first and only once-daily, oral menin inhibitor approved for this R/R NPM1‑mutated AML population.

Approval is supported by the pivotal KOMET‑001 trial in 112 patients, showing a complete remission (CR) plus CR with partial hematologic recovery (CRh) rate of 21.4% (95% CI: 14.2, 30.2). Median duration of CR+CRh was 5.0 months (95% CI: 1.9, 8.1), and median time to first response among responders was 2.7 months, with 88% achieving CR or CRh within six months of starting therapy. The label includes a Boxed Warning for differentiation syndrome, and common adverse reactions (≥20%) included liver enzyme elevations, infections, electrolyte changes, hemorrhage, gastrointestinal events, fatigue, edema, and QTc interval prolongation (≤ Grade 3 in 12% of patients; no Grade 4/5 reported). The wholesale acquisition cost for a one‑month supply is $48,500. Kura leads U.S. development, regulatory and commercial strategy and manufacturing under its collaboration with Kyowa Kirin; Kyowa Kirin leads outside the United States.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
current report
Rhea-AI Summary

Kura Oncology (KURA) filed a Form S-8 to register 750,000 additional shares of common stock issuable under its 2023 Inducement Option Plan, as amended. The increase to the plan’s share reserve was approved by the Board of Directors pursuant to Nasdaq Listing Rule 5635(c)(4).

The filing incorporates prior S-8 registrations for the same plan and adds capacity for future inducement equity awards to eligible new employees.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
registration
-
Form 10-Q
Rhea-AI Summary

Kura Oncology (KURA) reported Q3 2025 results with collaboration revenue of $20.8 million, driven by its Kyowa Kirin partnership, and a net loss of $74.1 million ($0.85 per share). Operating expenses rose to $100.7 million on higher R&D ($67.9 million) and G&A ($32.8 million).

Liquidity remained strong with $549.7 million in cash, cash equivalents and short-term investments as of September 30, 2025. Contract liabilities tied to deferred collaboration revenue totaled $317.6 million, reflecting services to be delivered; receivables from collaborators were $35.9 million. Shares outstanding were 87.0 million as of October 31, 2025.

The company’s NDA for ziftomenib in relapsed/refractory NPM1-mutated AML was accepted with Priority Review and a PDUFA target action date of November 30, 2025. Kura also amended its term loan on October 25, 2025 to extend interest-only payments, with a further extension possible upon an approval milestone.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
quarterly report
-
Rhea-AI Summary

Kura Oncology (KURA) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025, along with a corporate update.

The information under Item 2.02 and Exhibit 99.1 is being furnished, not deemed “filed” under Section 18 of the Exchange Act, and will not be incorporated by reference into Securities Act registrations unless specifically identified.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
current report
Rhea-AI Summary

Kura Oncology announced receipt of a $30 million milestone payment from Kyowa Kirin. The payment was triggered by dosing the first patient in KOMET-017, a pair of Phase 3 registrational trials evaluating ziftomenib, a once-daily, investigational oral menin inhibitor.

KOMET-017 consists of two independent, global, randomized double-blind, placebo-controlled Phase 3 studies. They assess ziftomenib in combination with intensive and non‑intensive chemotherapy in adults with newly diagnosed NPM1‑mutated or KMT2A‑rearranged acute myeloid leukemia. The payment provides non-dilutive funding aligned with the advancement of ziftomenib into late‑stage testing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
current report

FAQ

How many Kura Oncology (KURA) SEC filings are available on StockTitan?

StockTitan tracks 130 SEC filings for Kura Oncology (KURA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Kura Oncology (KURA)?

The most recent SEC filing for Kura Oncology (KURA) was filed on November 19, 2026.